Literature DB >> 18204266

Childhood craniopharyngioma. Recent advances in diagnosis, treatment and follow-up.

Hermann L Muller1.   

Abstract

BACKGROUND: Craniopharyngioma are embryogenic malformations of the sellar area. With an overall incidence of 0.5-2 new cases per million population per year, 30-50% of all cases occur in childhood. Overall survival rates are high. However, quality of life (QoL) is substantially reduced in many survivors due to sequelae such as extreme obesity caused by hypothalamic lesions.
METHODS: Based on retrospective analysis of 306 patients with childhood craniopharyngioma (HIT ENDO), we found that QoL was negatively related to hypothalamic involvement, tumor size and the number of neurosurgical interventions.
RESULTS: Irradiation had no significant impact on long-term QoL. The prospective surveillance of 98 patients in KRANIOPHARYNGEOM 2000 revealed frequent and early events in terms of tumor relapse after apparently complete resection (EFS: 0.60 +/- 0.09 at 3 years) and tumor progression after incomplete resection (EFS: 0.22 +/- 0.09).
CONCLUSION: We conclude that radical surgery in patients with hypothalamic involvement has a major negative impact on long-term QoL. Innovative treatment strategies are warranted to improve QoL in these patients at risk. Accordingly, the appropriate time point of irradiation after incomplete resection will be analyzed in KRANIOPHARYNGEOM 2007. (c) 2008 S. Karger AG, Basel

Entities:  

Mesh:

Year:  2008        PMID: 18204266     DOI: 10.1159/000113019

Source DB:  PubMed          Journal:  Horm Res        ISSN: 0301-0163


  42 in total

1.  Rapid recurrence of craniopharyngioma following recombinant human growth hormone replacement.

Authors:  Takafumi Taguchi; Toshihiro Takao; Yasumasa Iwasaki; Kyonghon Pooh; Mizuho Okazaki; Kozo Hashimoto; Yoshio Terada
Journal:  J Neurooncol       Date:  2010-03-28       Impact factor: 4.130

Review 2.  Childhood craniopharyngioma--current concepts in diagnosis, therapy and follow-up.

Authors:  Hermann L Müller
Journal:  Nat Rev Endocrinol       Date:  2010-09-28       Impact factor: 43.330

3.  First experiences with neuropsychological effects of oxytocin administration in childhood-onset craniopharyngioma.

Authors:  Anika Hoffmann; Jale Özyurt; Kristin Lohle; Julia Reichel; Christiane M Thiel; Hermann L Müller
Journal:  Endocrine       Date:  2017-02-17       Impact factor: 3.633

Review 4.  Pediatric Craniopharyngiomas: A Primer for the Skull Base Surgeon.

Authors:  Christopher Salvatore Graffeo; Avital Perry; Michael J Link; David J Daniels
Journal:  J Neurol Surg B Skull Base       Date:  2018-01-19

Review 5.  Excess mortality after craniopharyngioma treatment: are we making progress?

Authors:  Nidan Qiao
Journal:  Endocrine       Date:  2018-12-19       Impact factor: 3.633

Review 6.  Pediatric sellar and suprasellar lesions.

Authors:  Jason W Schroeder; L Gilbert Vezina
Journal:  Pediatr Radiol       Date:  2011-01-26

7.  A novel rodent model that mimics the metabolic sequelae of obese craniopharyngioma patients.

Authors:  Christian L Roth; James E Blevins; Melissa Ralston; Clinton Elfers; Kayoko Ogimoto; Karl J Kaiyala; Gregory J Morton
Journal:  Pediatr Res       Date:  2011-03       Impact factor: 3.756

8.  Sixty years single institutional experience with pediatric craniopharyngioma: between the past and the future.

Authors:  Mohammed A Fouda; R Michael Scott; Karen J Marcus; Nicole Ullrich; Peter E Manley; Mark W Kieran; Liliana C Goumnerova
Journal:  Childs Nerv Syst       Date:  2019-07-10       Impact factor: 1.475

9.  Longitudinal investigation of adaptive functioning following conformal irradiation for pediatric craniopharyngioma and low-grade glioma.

Authors:  Kelli L Netson; Heather M Conklin; Shengjie Wu; Xiaoping Xiong; Thomas E Merchant
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-12-11       Impact factor: 7.038

10.  Trends in treatment and outcomes of pediatric craniopharyngioma, 1975-2011.

Authors:  Michal Cohen; Ute Bartels; Helen Branson; Abhaya V Kulkarni; Jill Hamilton
Journal:  Neuro Oncol       Date:  2013-03-13       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.